Form 4: BridgeBio CAO Apuli Reports Tax-Related Stock Sale

BridgeBio Pharma's Chief Accounting Officer, Maricel Apuli, reported the disposition of 2,003 common shares to cover tax obligations related to RSU vesting.

Summary

• Maricel Apuli, Chief Accounting Officer of BridgeBio Pharma, Inc., reported a transaction involving the company's common stock.
• On December 12, 2025, 2,003 shares of common stock were disposed of at a price of $75.15 per share.
• This disposition was a 'F' transaction code, indicating shares withheld to satisfy tax obligations.
• The shares were withheld in connection with the vesting of 3,944 Restricted Stock Units (RSUs).
• Following this transaction, Apuli beneficially owns 128,294 shares of BridgeBio Pharma common stock.

Sentiment

Score: 5

Explanation: The filing reports a routine tax-related disposition of shares following RSU vesting, which is a neutral event reflecting standard executive compensation practices. It does not indicate any positive or negative operational or financial performance.

Positives

• The transaction indicates the vesting of 3,944 Restricted Stock Units (RSUs) for the Chief Accounting Officer, which is a positive event for the executive.

Negatives

• No direct negatives from this specific tax-related disposition.

Future Outlook

No forward-looking statements or guidance are provided.

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting an executive's compensation event rather than a strategic industry development. It does not provide specific insights into broader industry trends or competitive landscape.

Comparison to Industry Standards

• This is a standard Form 4 filing reporting a tax-related disposition of shares following RSU vesting, which is a common compensation practice for executives across publicly traded companies. There are no specific comparable companies, projects, or results to detail as this is an individual executive compensation event.

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors, as this is a routine, tax-related transaction by an individual executive. It reflects standard compensation practices.

Key Dates

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Transaction, Maricel Apuli, Chief Accounting Officer, Restricted Stock Units, RSU Vesting, Tax Withholding, Common Stock